Researchers from Zjengzhou University reported on the discovery and preclinical characterization of a novel PROTAC agent aimed at overcoming paclitaxel (Taxol) resistance in non-small-cell lung cancer treatment.
Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.
Tropomyosin receptor kinases (TRKs), encoded by neurotrophic receptor tyrosine kinase (NTRK) genes, are involved in cell proliferation, differentiation and apoptosis, and are validated therapeutic targets for cancer treatment.
Ono Pharmaceutical Co. Ltd. has entered into an option and collaboration agreement with Numab Therapeutics AG to develop and commercialize a novel multispecific macrophage engager, NM-49, in oncology.
Researchers at Oncopia Therapeutics Inc. (Proteovant Therapeutics Inc.) and University of Michigan have divulged conjugates comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to an estrogen receptor (ER) or zinc finger protein Helios (IKZF2) and/or zinc finger protein Aiolos (IKZF3) moiety through a linker.
RSS
